Literature DB >> 17600548

Serum nitric oxide metabolite (NO(x)) levels in hypertensive patients at rest: a comparison of age, gender, blood pressure and complications using normotensive controls.

Hideaki Higashino1, Hirohisa Miya, Hidenori Mukai, Yoshihisa Miya.   

Abstract

1. Hypertensive patients have pathophysiological changes such as atherosclerosis, endothelial dysfunction and inflammations. The patients' serum nitric oxide metabolite (nitrate/nitrite; NO(x)) levels were measured in peripheral blood using normotensive controls for comparison. 2. The NO(x) levels in 175 hypertensive patients with or without comorbid diseases (aged 37-95 years; average 50.6 +/- 0.8 years) were compared with those in 80 normotensive controls (aged 25-73 years; average 37.1 +/- 1.8 years). 3. The NO(x) levels increased with age in both the normotensive and hypertensive women, but not in men. No difference was noted in the NO(x) levels between the normotensive and hypertensive patients without comorbid diseases. The mean value of NO(x) in male hypertensive patients aged under 50 years was close to that of female patients aged 51-60 years. Hypertensive males aged 61-70 years showed almost the same NO(x) levels as those of female patients aged over 81 years. A male group of hypertensive patients with diabetes, hyperlipaemia and renal disorder had a significantly higher NO(x) level compared with a normotensive control group. However, in female groups, only hypertensive patients with hyperlipaemia showed higher serum NO(x) values compared with the normotensive group. 4. These findings suggest that: (i) the occurrence of NO(x) in the serum is not solely the outcome of high blood pressure; (ii) higher serum NO(x) levels in older women are because of an oestrogen deficiency-induced cardiovascular disease; (iii) ageing effects on the circulation system are more apparent in men than in women; and (iv) measurement of NO(x) levels in the serum is helpful for understanding the pathological progress in male hypertensive patients with diseases such as diabetes mellitus, hyperlipaemia and renal disorder.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17600548     DOI: 10.1111/j.1440-1681.2007.04617.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  8 in total

Review 1.  Is nitric oxide a hormone?

Authors:  Asghar Ghasemi; Saleh Zahediasl
Journal:  Iran Biomed J       Date:  2011

2.  Endothelial nitric oxide synthase (G894T) gene polymorphism in a random sample of the Egyptian population: comparison with myocardial infarction patients.

Authors:  Mohamed Z Gad; Mohamed F Abdel Rahman; Ingy M Hashad; Sahar M Abdel-Maksoud; Nabil M Farag; Khaled Abou-Aisha
Journal:  Genet Test Mol Biomarkers       Date:  2012-06-25

Review 3.  Nitrite in organ protection.

Authors:  Tienush Rassaf; Peter Ferdinandy; Rainer Schulz
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 4.  Endothelial nitric oxide (NO) and its pathophysiologic regulation.

Authors:  Anuran Chatterjee; Stephen M Black; John D Catravas
Journal:  Vascul Pharmacol       Date:  2008-07-20       Impact factor: 5.773

5.  Nitric oxide and clustering of metabolic syndrome components in pediatrics.

Authors:  Asghar Ghasemi; Saleh Zahediasl; Fereidoun Azizi
Journal:  Eur J Epidemiol       Date:  2009-08-22       Impact factor: 8.082

6.  Hyperglycaemia enhances nitric oxide production in diabetes: a study from South Indian patients.

Authors:  Ramu Adela; Susheel Kumar Nethi; Pankaj K Bagul; Ayan K Barui; Saidulu Mattapally; Madhusudan Kuncha; Chitta R Patra; P Naveen Chander Reddy; Sanjay K Banerjee
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

7.  Roles of insulin, age, and asymmetric dimethylarginine on nitric oxide synthesis in vivo.

Authors:  Paolo Tessari; Diego Cecchet; Carlo Artusi; Monica Vettore; Renato Millioni; Mario Plebani; Lucia Puricelli; Monica Vedovato
Journal:  Diabetes       Date:  2013-03-08       Impact factor: 9.461

8.  Sex-Related Difference in Nitric Oxide Metabolites Levels after Nephroprotectant Supplementation Administration against Cisplatin-Induced Nephrotoxicity in Wistar Rat Model: The Role of Vitamin E, Erythropoietin, or N-Acetylcysteine.

Authors:  Mehdi Nematbakhsh; Zahra Pezeshki
Journal:  ISRN Nephrol       Date:  2013-03-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.